Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Ending Cash Position : $322 Mil (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Ending Cash Position?

Tianjin Pharmaceutical Da Ren Tang Group's Ending Cash Position for the quarter that ended in Mar. 2024 was $322 Mil.

Tianjin Pharmaceutical Da Ren Tang Group's quarterly Ending Cash Position increased from Sep. 2023 ($264 Mil) to Dec. 2023 ($280 Mil) and increased from Dec. 2023 ($280 Mil) to Mar. 2024 ($322 Mil).

Tianjin Pharmaceutical Da Ren Tang Group's annual Ending Cash Position increased from Dec. 2021 ($358 Mil) to Dec. 2022 ($389 Mil) but then declined from Dec. 2022 ($389 Mil) to Dec. 2023 ($280 Mil).

Tianjin Pharmaceutical Da Ren Tang Group Ending Cash Position Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Ending Cash Position Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

210.93

303.91

358.47

388.93

279.74

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															478.00	279.49	264.29	279.74	322.00

Tianjin Pharmaceutical Da Ren Tang Group Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Tianjin Pharmaceutical Da Ren Tang Group's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	379.756	+	-100.018
	=	280

Tianjin Pharmaceutical Da Ren Tang Group's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	277.357	+	44.647
	=	322

Tianjin Pharmaceutical Da Ren Tang Group Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SGX:T14) » Definitions » Ending Cash Position

Traded in Other Exchanges

600329:China

Address

No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193

Website

http://www.jydrt.com.cn

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Headlines

No Headlines